Qiagen, a CataloniaBio & HealthTech member with a subsidiary in Barcelona, announced it has received emergency-use authorisation from the U.S. Food and Drug Administration (FDA) for its QIAstat-Dx Respiratory SARS-CoV-2 test to diagnose patients infected with the Covid-19.
QIAstat-Dx delivers results in about an hour and is the first testing solution to be deployed in the pandemic that can differentiate the novel coronavirus from 20 other serious respiratory infections.
The technology for the new test comes from Catalan company STAT-Dx, which Qiagen acquired in 2018.
Comments